NCT01392235

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

A Single-arm, Open, Multicenter, Phase II Study of Famitinib as ≥Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable. PURPOSE: This phase II trial is studying how well famitinib works in treating patients with recurrent and/or metastatic NPC.

Conditions

• Recurrent Nasopharyngeal Carcinoma
• Metastatic Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Famitinib	25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Timeline

• Start date: 2011-07-01
• Primary completion: 2015-04-01
• Completion: 2016-08-01
• First posted: 2011-07-12
• Last updated: 2019-01-22

Locations

1 site across 1 country: China